A New Variant of 16S rRNA Methylase, RmtD3, in a Clinical Isolate of Pseudomonas aeruginosa in Myanmar

Antimicrob Agents Chemother. 2017 Dec 21;62(1):e01806-17. doi: 10.1128/AAC.01806-17. Print 2018 Jan.

Authors

Tatsuya Tada^{1

2}, Kayo Shimada², San Mya³, Khin Nyein Zan³, Kyoko Kuwahara¹, Teruo Kirikae^{4

2}, Htay Htay Tin³

Affiliations

¹ Department of Microbiology, Juntendo University School of Medicine, Tokyo, Japan.
² Department of Infectious Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
³ National Health Laboratory, Yangon, Myanmar.
⁴ Department of Microbiology, Juntendo University School of Medicine, Tokyo, Japan t-kirikae@juntendo.ac.jp.

No abstract available

Keywords: 16S rRNA methylase; Myanmar; Pseudomonas aeruginosa; RmtD3; aminoglycoside resistance.

Publication types

Letter

MeSH terms

Aminoglycosides / pharmacology
Anti-Bacterial Agents / pharmacology
Drug Resistance, Bacterial / genetics
Humans
Methyltransferases / genetics
Microbial Sensitivity Tests / methods
Myanmar
Pseudomonas aeruginosa / drug effects
Pseudomonas aeruginosa / genetics*
Pseudomonas aeruginosa / isolation & purification*
RNA, Ribosomal, 16S / genetics*

Substances

Aminoglycosides
Anti-Bacterial Agents
RNA, Ribosomal, 16S
Methyltransferases
rRNA (adenosine-O-2'-)methyltransferase